Evidence map›Paper›PMID 39943795›Full record

ReviewExpert review of anticancer therapy2025

Persisting challenges in the early detection of hepatocellular carcinoma.

Ashwini Arvind, Kennedy Redmon, Amit G Singal

Abstract readReview
In one paragraph

Review in Expert review of anticancer therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ashwini ArvindDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Kennedy RedmonDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Amit G SingalDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-1172-3971

Funding

The Early Detection Research Network: Data Management and Coordinating CenterU24CA086368 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RUTH D ETZIONI, Ziding Feng · 2010 to 2026
$75.7M
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United StatesU01CA230694 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2018 to 2022
$3.5M
Harms of Hepatocellular Carcinoma Screening in Patients with CirrhosisR01CA212008 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2017 to 2022
$3.2M
Precision Screening for Hepatocellular Carcinoma in Patients with CirrhosisR01CA222900 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2018 to 2023
$2.4M
NCI NIH HHS R01 CA212008NCI NIH HHS R01 CA222900NCI NIH HHS U01 CA230694NCI NIH HHS U24 CA086368
6 · The paper itself

Abstract

introductionPrognosis in patients with HCC is largely determined by stage at diagnosis, highlighting the importance of effective early detection strategies. HCC surveillance is associated with increased early detection and reduced HCC-related mortality and is currently recommended in patients with cirrhosis or chronic HBV infection. AREAS COVERED: We performed a targeted literature review to identify limitations of current HCC surveillance practices and strategies for improvement. EXPERT OPINION: Semi-annual ultrasound continues as the cornerstone modality for HCC surveillance but has limited sensitivity for detecting early-stage HCC, particularly in patients with obesity and non-viral etiologies. Although sensitivity for early-stage HCC can be improved by using ultrasound with alpha fetoprotein, this strategy misses over one-third of HCC at an early stage. Emerging imaging and biomarker-based surveillance strategies currently remain in varying stages of validation and are not yet ready for routine use in practice. The cost-effectiveness of surveillance in patients with non-cirrhotic liver disease related to hepatitis C or metabolic dysfunction-associated steatotic liver disease continues to be debated, although subgroups with advanced fibrosis may warrant surveillance. Finally, the effectiveness of surveillance is diminished by underuse in clinical practice, particularly in racial minority and low-income groups, highlighting a need for interventions to increase utilization.

Indexed as

hepatocellular carcinomaLiver cancerscreeningsurveillanceultrasound

Identifiers

PMID39943795
PMCPMC12353231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.